Cardiovascular
and Renal Drugs Advisory Committee
Meeting
Agenda
Chair, Cardiovascular and Renal Drugs
Advisory Committee
Conflict
of Interest Statement Dornette
Spell-LeSane, M.H.A., NP-C
Executive
Secretary, FDA
Division
of Cardiovascular and Renal Drugs
FDA
The committee will discuss new drug application
NDA 21-526 CV Therapeutics
Proposed tradename Ranexa (ranolazine) 375 mg and
500 mg tablets
for treatment of chronic stable angina
CV Therapeutics
10:15
– 10:30 Break